Kura Oncology (NASDAQ:KURA) Cut to Hold at Stifel Nicolaus

Stifel Nicolaus cut shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a report published on Monday, MarketBeat Ratings reports. The firm currently has $19.00 target price on the stock, down from their prior target price of $26.00.

Several other analysts also recently weighed in on the company. JMP Securities restated a market outperform rating and set a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. StockNews.com downgraded Kura Oncology from a hold rating to a sell rating in a research note on Thursday, August 22nd. Cantor Fitzgerald restated an overweight rating on shares of Kura Oncology in a research note on Monday, September 9th. Wedbush restated an outperform rating and set a $37.00 target price on shares of Kura Oncology in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a buy rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and an average price target of $29.20.

Kura Oncology Stock Down 2.8 %

Shares of NASDAQ KURA opened at $18.06 on Monday. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The company has a market cap of $1.38 billion, a P/E ratio of -8.32 and a beta of 0.84. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average price of $19.58 and a 200 day moving average price of $20.27.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the company earned ($0.53) earnings per share. Research analysts anticipate that Kura Oncology will post -2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently bought and sold shares of the company. Quarry LP acquired a new position in Kura Oncology in the second quarter valued at approximately $196,000. Alethea Capital Management LLC boosted its stake in Kura Oncology by 2.4% in the second quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after acquiring an additional 6,300 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares during the period. AQR Capital Management LLC boosted its stake in Kura Oncology by 251.5% in the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after acquiring an additional 58,422 shares during the period. Finally, Armistice Capital LLC boosted its stake in Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.